TNRC6A

Across TCGA pan-cancer cohorts, TNRC6A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TNRC6A data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TNRC6A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TNRC6A expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where TNRC6A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.836	1.000	.008	21	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.843	.037	3	view →
LUAD	DFS	Quartile	II,III,IV	0.409	1.000	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TNRC6A–CCRCC (DFS)

Open the CCRCC breakdown →